

Zunveyl[®] (benzgalantamine) – New drug approval

- On July 29, 2024, [Alpha Cognition announced](#) the FDA approval of [Zunveyl \(benzgalantamine\)](#), for the treatment of mild to moderate dementia of the Alzheimer's type in adults.
- Zunveyl is an acetylcholinesterase inhibitor and a prodrug of galantamine.
- The efficacy of Zunveyl is based upon 3 bioavailability studies in healthy adults comparing galantamine immediate-release tablets and galantamine extended-release capsules to Zunveyl.
- Warnings and precautions for Zunveyl include serious skin reactions, anesthesia, cardiovascular conditions, gastrointestinal conditions, genitourinary conditions, neurological conditions, and pulmonary conditions.
- The most common adverse reactions ($\geq 5\%$) with Zunveyl use were nausea, vomiting, diarrhea, dizziness, headache, and decreased appetite.
- The recommended starting dose of Zunveyl is 5 mg orally twice a day (10 mg/day). Dose should be increased to initial maintenance dosage of 10 mg twice daily (20 mg/day) after a minimum of 4 weeks, based on clinical response and tolerability. Dosage may be increased to the maximum recommended dosage of 15 mg twice a day (30 mg/day) after a minimum of 4 weeks at 10 mg twice daily.
- Aimmune Therapeutics plans to launch Zunveyl in the first quarter of 2025. Zunveyl will be available as a 5 mg, 10 mg, and 15 mg delayed-release tablets.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.